Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

E R Petersen; C Ammitzbøll; H B Søndergaard; A B Oturai; P S Sørensen; A C Nilsson; L Börnsen; M von Essen; F Sellebjerg

doi:10.1016/j.jneuroim.2019.577085

Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

E R Petersen, C Ammitzbøll, H B Søndergaard, A B Oturai, P S Sørensen, A C Nilsson, L Börnsen, M von Essen, F Sellebjerg

Afdeling for Hjerne- og Nervesygdomme

9 Citationer (Scopus)

Abstract

The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

Originalsprog	Engelsk
Tidsskrift	Journal of Neuroimmunology
Vol/bind	337
Sider (fra-til)	577085
ISSN	0165-5728
DOI	https://doi.org/10.1016/j.jneuroim.2019.577085
Status	Udgivet - 15 dec. 2019

Adgang til dokumentet

10.1016/j.jneuroim.2019.577085

Citationsformater

@article{1ef07022f677422b8f55f692d8e36238,

title = "Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis",

abstract = "The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.",

keywords = "Adult, Aged, CD146 Antigen/biosynthesis, CD4-Positive T-Lymphocytes/drug effects, Cohort Studies, Female, Gene Expression, Humans, Immunologic Factors/administration & dosage, Infusions, Intravenous, Male, Middle Aged, Multiple Sclerosis/blood, Natalizumab/administration & dosage, Prospective Studies, Young Adult",

author = "Petersen, {E R} and C Ammitzb{\o}ll and S{\o}ndergaard, {H B} and Oturai, {A B} and S{\o}rensen, {P S} and Nilsson, {A C} and L B{\"o}rnsen and {von Essen}, M and F Sellebjerg",

year = "2019",

month = dec,

day = "15",

doi = "10.1016/j.jneuroim.2019.577085",

language = "English",

volume = "337",

pages = "577085",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

AU - Petersen, E R

AU - Ammitzbøll, C

AU - Søndergaard, H B

AU - Oturai, A B

AU - Sørensen, P S

AU - Nilsson, A C

AU - Börnsen, L

AU - von Essen, M

AU - Sellebjerg, F

PY - 2019/12/15

Y1 - 2019/12/15

N2 - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

AB - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

KW - Adult

KW - Aged

KW - CD146 Antigen/biosynthesis

KW - CD4-Positive T-Lymphocytes/drug effects

KW - Cohort Studies

KW - Female

KW - Gene Expression

KW - Humans

KW - Immunologic Factors/administration & dosage

KW - Infusions, Intravenous

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis/blood

KW - Natalizumab/administration & dosage

KW - Prospective Studies

KW - Young Adult

U2 - 10.1016/j.jneuroim.2019.577085

DO - 10.1016/j.jneuroim.2019.577085

M3 - Journal article

C2 - 31655423

SN - 0165-5728

VL - 337

SP - 577085

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

ER -

Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater